Medicare, Medicaid Rx Price Reporting Are IG Review Priorities For 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS Inspector General will conduct several reviews related to drug manufacturers' price reporting for Medicare and Medicaid, IG's fiscal 2005 work plan says
You may also be interested in...
FDA Oversight Of DTC Ads Will Be Examined By HHS Inspector General
The Inspector General will determine the effectiveness of FDA procedures for monitoring DTC ads and what actions are taken against companies with false and misleading ads, the IG’s fiscal 2005 work plan says. FDA’s handling of off-label drug promotions will also be studied.
FDA Oversight Of DTC Ads Will Be Examined By HHS Inspector General
The Inspector General will determine the effectiveness of FDA procedures for monitoring DTC ads and what actions are taken against companies with false and misleading ads, the IG’s fiscal 2005 work plan says. FDA’s handling of off-label drug promotions will also be studied.
Average Sales Price Final Rule Includes PhRMA's Estimation Method
Calculations of ASP for Medicare Part B drugs will be based on a rolling average percentage of price concessions divided by total sales, as proposed in manufacturers' comments. The final rule will be published Sept. 16.